At what enterprise value was DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) acquired in 2026?

During the acquisition of DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) by CVC in 2026, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Industry & Manufacturing industry currently tracks an average EBITDA multiple of 11.1x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) when it was acquired by CVC?

The estimated EV/EBITDA multiple for DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) is in the range of 5x - 12x. For comparison, the Industry & Manufacturing sector currently shows an average EBITDA multiple of 11.1x. Join our community for free to access full valuation data and industry trends.

What was the revenue of DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) at the time of the deal?

The revenue of DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) at the time of the deal is estimated to be in the range of 2.5b - 5b EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) during the acquisition?

DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH)'s EBITDA is estimated to be in the range of 250M - 500M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.pehub.com/cvc-to-buy-animal-nutrition-health-from-dsm-firmenich-in-e2-2bn-deal/

← DATABASE

Home Database Industry & ManufacturingDSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH)

02/2026

DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) acquired by CVC

SWITZERLAND Chemicals & Materials / Specialty Chemicals / Nutrition EV 1b - 4b EUR

Context

DSM-Firmenich has agreed to sell a majority interest in its Animal Nutrition and Health (ANH) business to CVC Capital Partners. Under the terms of the agreement, DSM-Firmenich will retain a 20% minority stake to benefit from future upside. The transaction structure involves a combination of cash proceeds (~EUR600 million) and the transfer of debt/liabilities (~EUR500 million) to the new standalone entity. Additionally, the deal includes an earn-out component based on future performance. Post-closing, the business will be operationally split into two separate entities: "Solutions Company" and "Essential Products Company," both headquartered in Switzerland. A long-term supply agreement has been established to ensure the ongoing provision of vitamins between the parent and the divested entities.

DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH), which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Industry & Manufacturing sector (11.1x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Industry & Manufacturing market trends

Target

The Animal Nutrition & Health (ANH) division of DSM-Firmenich is one of the world's largest suppliers of vitamins, carotenoids, eubiotics, and feed enzymes for the livestock industry. Headquartered in Kaiseraugst (Switzerland), the division employs approximately 8,000 people.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Industry & Manufacturing

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2026	INTERNATIONAL PAPER COMPANY	NORPAC	UNITED STATES	Chemicals & Materials	The group has finalized an agreement to acquire the target from One Rock Capital Partners, a maneuver designed to fundamentally expand its manufacturing capabilities in the growing West Coast region. The strategic rationale for this transaction centers on a "network-flexibility" play, merging the target's industry-leading technical operational depth in recycled fiber milling with the group’s established global distribution and containerboard framework
04/2026	LIFCO	METALLTECH	ITALY	Chemicals & Materials	The Swedish investment holding has signed a definitive agreement to acquire a majority interest in the target, marking its first transaction in the Italian market for the 2026 fiscal year. This operation follows a high-velocity acquisition pipeline aimed at consolidating a portfolio of high-performing "Made in Italy" industrial champions
02/2026	STRATUS PACKAGING	FREPPEL IMPRIMEUR	FRANCE	Chemicals & Materials	Stratus Packaging acquired Freppel Imprimeur to strengthen its geographic coverage in Eastern France (Alsace) and Germany. This integration allows Stratus to pass the milestone of EUR100M in turnover and consolidate its position in the wine, spirits, and luxury markets
02/2026	HENKEL	STAHL	NETHERLANDS	Chemicals & Materials	Wendel signed an agreement for the sale of the entire share capital of Stahl to the German industrial group Henkel. The transaction was intermediated by two leading international investment banks. This operation marks the exit of Wendel after a 20-year investment period, as well as the exit of industrial partners BASF and Clariant
02/2026	MEARTHANE PRODUCTS CORPORATION	AXILLON AEROSPACE - POLYURETHANE	UNITED STATES	Chemicals & Materials	This corporate carve-out transaction marks the full acquisition of Axillon Aerospace’s industrial composites business by Mearthane Products Corporation, representing the platform's latest programmatic transaction over a multi-year period and accelerating its long-term capital deployment strategy
02/2026	SAGARD	ESSENCES & PARFUMS	FRANCE	Chemicals & Materials	Sagard acquired a majority stake in Essences & Parfums from Trajan, which exited the business alongside minority investors Bpifrance, Smalt Capital, and the original founders. The transaction, completed following a swift three-month competitive process managed by an investment bank, saw strong interest from both financial sponsors and industrial players
02/2026	ONE EQUITY PARTNERS	GIOVANNI BOZZETTO	ITALY	Chemicals & Materials	One Equity Partners acquired a majority stake in Giovanni Bozzetto from the Canadian diversified holding company Aimia Inc. and Paladin Private Equity. The transaction followed Aimia's brief ownership period (since May 2023), during which the group expanded into Central America via the acquisition of StarChem
01/2026	SNF GROUP	SYENSQO OIL & GAS BUSINESS UNIT	BELGIUM	Chemicals & Materials	Syensqo has finalized the divestment of its Oil & Gas Business Unit to SNF Group. The strategic rationale for the sale is to advance Syensqo’s "pure play specialty" strategy, allowing the company to sharpen its strategic focus and reallocate capital toward its core science-led businesses
01/2026	ARKEA CAPITAL	GROUPE BARTOLAC	FRANCE	Chemicals & Materials	Arkea Capital acquired a 20% stake in Bartolac, marking the first time the family-owned group has opened its capital to an outside investor. The transaction facilitates the financial exit of the founding generation while supporting the second generation (Planeix family)
12/2025	HOLCIM GROUP	ALKERN	FRANCE	Chemicals & Materials	Holcim has finalized the 100% acquisition of Alkern from the private equity firm Chequers Capital. This transaction marks the final exit for Chequers, which had supported Alkern’s growth since 2016. The strategic rationale for Holcim is the immediate reinforcement of its "Construction Solutions" pillar in the French market, positioning it alongside its existing Lafarge and PRB operations

REFERENCES

Valuation range: EV 1b - 4b EUR

Revenue range: 2.5b - 5b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DSM-FIRMENICH ANH (ANIMAL NUTRITION & HEALTH) by CVC are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: cvc